Outbreak of methanol-induced optic neuropathy in early COVID-19 era; effectiveness of erythropoietin and methylprednisolone therapy

Table 2 Previous studies of methanol-induced optic neuropathy treated with erythropoietin

Ref.	Type of study	No. of patients	Age (yr)1/Sex	Time interval1	Management	No. of Courses	Pre VA	Post VA	Follow-up1
Pakravan et al[35], 2012	Case report	2	30/M	3 d	IV EPO 10000 IU BID for 3 d	1	OU: NLP	OU: 20/20	3 wk
			35/M	7 d	IV Methylprednisolone 500 mg BID for 5 d followed by 2 wk of oral prednisolone 1 mg/kg/d, Vitamin B6 100 mg/d, vitamin B12 100mg/d, and folic acid 10 mg/d for 1 mo		OU: NLP	OD: CF; OS: 20/30	2 wk
Pakravan et al[36], 2016	Nonrandomized interventional comparative	11	34.5/M	4.8 ± 2.6 d	IV EPO 10000 IU BID for 3 d, IV Methylprednisolone 500 mg BID for 5 d followed by 2 wk of oral prednisolone 1 mg/kg/d, Vitamin B6 100 mg/d, vitamin B12 100 mg/d, and folic acid 10 mg/d for 1 mo	1	2.93 ± 0.55 LogMAR	1.75 ± 1.16 LogMAR	3 mo
Zamani et al[38], 2018	Case-control	10	34/NA	2 d	SQ EPO 10000 IU BID for 3 d, Methylprednisolone 250 mg QID for 3 d	1	0.002	0.004	2 mo
Pakdel et al[38], 2018	Case-series	16	34.2/15 M	9.1 d	IV EPO 20000 IU QD for 3 d	3 in six cases, 2 in eight, 1 in two	Better eye: 3.6 LogMAR	Better eye: 1.0 LogMAR	7.5 mo

¹mean.

M: Male; BID: Twice; QID: 4 times per day; QD: Daily; VA: Visual acuity; OU: Both eyes; OD: Right eye; OS: Left eye; NLP: No light perception; CF: Counting fingers; IV: Intravenous; SQ: Subcutaneous; NA: Not available; EPO: Erythropoietin; LogMAR: Logarithm of the minimum angle of resolution.